Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy, safety and tolerability of ER niacin + laropiprant versus ER niacin in dyslipidemia
2009-012772-27Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in dyslipidemia comparing ERN/LRPT (Tredaptive) with Extended-release niacin + placebo (2 arms). Primary endpoint: Number of days per week with GFSS > 4 during weeks 21 to 32. Started Sep 2009; status: completed.
02
Drugs
laropiprant
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on 2009-012772-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012772-27.